Nocturia: Etiology, diagnosis, and treatment

被引:63
作者
Appell, Rodney A. [1 ]
Sand, Peter K. [2 ]
机构
[1] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA
[2] Northwestern Univ, Sch Med, Div Urogynecol & Reconstruct Pelv Surg, Chicago, IL 60611 USA
关键词
antimuscarinics; diagnosis; nocturia;
D O I
10.1002/nau.20484
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Voiding at night, or nocturia, is a common reason for interrupted sleep in the adult population. The condition affects both men and women, with an incidence that increases dramatically with age. Nocturia has a negative impact on quality of life, affecting both morbidity and mortality. Effective diagnosis of the condition is dependent on a clear understanding of its underlying etiology. In general, the causes of nocturia fall into three categories: diurnal polyuria, nocturnal polyuria, and low bladder capacity. In some individuals, however, nocturnal polyuria and low bladder capacity may both contribute to the overall symptomatology of nocturia. Addressing any underlying conditions that contribute to nocturia is the first step in treating the condition. Lifestyle and behavioral changes may provide benefit in some individuals, but for many, the only option is pharmacotherapy. Antimuscarinic agents are first-line therapies for overactive bladder and are often used in the management of nocturia. Pharmacological and physicochemical differences between available antimuscarinic agents, however, translate into different safety and tolerability profiles, which may make some agents more suitable for use in certain populations, including the elderly. Careful selection of the most appropriate antimuscarinic medication is therefore central in optimizing treatment outcomes.
引用
收藏
页码:34 / 39
页数:6
相关论文
共 56 条
[1]   Solifenacin is effective for the treatment of OAB dry patients: A pooled analysis [J].
Abrams, P ;
Swift, S .
EUROPEAN UROLOGY, 2005, 48 (03) :483-487
[2]   The role of desmopressin in the treatment of adult nocturia [J].
Abrams, P ;
Mattiasson, A ;
Lose, GR ;
Robertson, GL .
BJU INTERNATIONAL, 2002, 90 :32-36
[3]   Antimuscarinics and the overactive detrusor - Which is the main mechanism of action? [J].
Andersson, KE ;
Yoshida, M .
EUROPEAN UROLOGY, 2003, 43 (01) :1-5
[4]   Bladder activation: Afferent mechanisms [J].
Andersson, KE .
UROLOGY, 2002, 59 (5A) :43-50
[5]   Nocturia in relation to sleep, health, and medical treatment in the elderly [J].
Asplund, R .
BJU INTERNATIONAL, 2005, 96 :15-21
[6]   Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes [J].
Beckmann-Knopp, S ;
Rietbrock, S ;
Weyhenmeyer, R ;
Böcker, RH ;
Beckurts, KT ;
Lang, W ;
Fuhr, U .
PHARMACOLOGY & TOXICOLOGY, 1999, 85 (06) :299-304
[7]  
Cannon A, 1999, BJU INT, V84, P20
[8]   A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial [J].
Chapple, CR ;
Martinez-Garcia, R ;
Selvaggi, L ;
Toozs-Hobson, P ;
Warnack, W ;
Drogendijk, T ;
Wright, DM ;
Bolodeoku, J .
EUROPEAN UROLOGY, 2005, 48 (03) :464-470
[9]   The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA [J].
Coyne, KS ;
Zhou, Z ;
Bhattacharyya, SK ;
Thompson, CL ;
Dhawan, R ;
Versi, E .
BJU INTERNATIONAL, 2003, 92 (09) :948-954
[10]   Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years [J].
Diefenbach, K ;
Arold, G ;
Wollny, A ;
Schwantes, U ;
Haselmann, J ;
Roots, I .
BJU INTERNATIONAL, 2005, 95 (03) :346-349